Impella 2.5™ and VA-ECMO Provide Hemodynamic Improvement in Patients with Cardiogenic Shock
Standard treatment of cardiogenic shock often includes the initiation of revascularization and the use of vasoconstrictors, inotropes, and the intra-aortic balloon pump. When cardiogenic shock resists traditional therapy, it can present a clinical challenge in addition to a substantially high mortality rate. Despite the advances in medicine and technology, cardiogenic shock maintains a mortality rate of a little less than 50%.1
Current options for refractory cardiogenic shock have grown to include not only the armamentarium of standard cardiogenic shock therapies, but also percutaneous mechanical circulatory support (MCS) devices like the Impella 2.5™. Additionally, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is often considered for patients with refractory cardiogenic shock, sometimes in combination with MCS devices, to help improve hemodynamic support.
A study from the November issue of the International Journal of Cardiology retrospectively examined in-hospital mortality for refractory cardiogenic shock patients receiving biventricular support from Impella 2.5™ and VA-ECMO. In about 71% of patients, the Impella 2.5™ was initiated before VA-ECMO.2
The center reporting biventricular support in this study notes that Impella 2.5™ is implanted first for cardiogenic shock caused by isolated left ventricular failure, whereas VA-ECMO is generally the first choice in the event of left ventricular failure and persistent cardiac arrest or pulmonary failure.
For the purpose of this study, refractory cardiogenic shock was defined by the following:
- Continual impaired end-organ perfusion despite aggressive medical therapy
- Persistent hypotension (systolic blood pressure less than 90 mmHg)
The use of inotropes and vasoconstrictors was significantly reduced 72 hours after biventricular support. Serum lactate, a prominent marker associated with cardiogenic shock, also decreased within the same time period for patients receiving concomitant therapy (Figure 1).
Figure 1 - Serum lactate levels of patients on biventricular supporta
Roughly half (44%) of treated patients with refractory cardiogenic shock received the dual treatment that allowed for ICU discharge to bridging to a long-term ventricular assist device or cardiac rehabilitation. The 28-day survival was 41%, however, possibly contributable to the critically ill patient selection for this study.
- Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294(4):448-454.
- Karatolios K, Chatzis G, Markus B, et al. Biventricular unloading in patients with refractory cardiogenic shock. Int J Cardiol. 2016;222:247-252.
Impella® Device — Indication & Safety Information
INDICATIONS FOR USE
IMPELLA® LEFT-SIDE DEVICES INDICATION & SAFETY INFORMATION
The Impella 2.5®, Impella CP® and Impella CP® with SmartAssist® Systems are temporary (≤ 6 hours) ventricular support devices indicated for use during high-risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5, Impella CP, and Impella CP with SmartAssist Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.
The Impella 2.5®, Impella CP®, Impella CP® with SmartAssist®, Impella 5.0® and Impella LD® Catheters, in conjunction with the Automated Impella® Controller (collectively, "Impella® System Therapy"), are temporary ventricular support devices intended for short term use (≤ 4 days for the Impella 2.5, Impella CP, and the Impella CP with SmartAssist, and ≤ 14 days for the Impella 5.0, and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP). The intent of Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function.
Important Risk Information for Impella devices
The Impella 2.5, Impella CP, Impella 5.0 and Impella LD are contraindicated for use with patients experiencing any of the following conditions: Mural thrombus in the left ventricle; Presence of a mechanical aortic valve or heart constrictive device; Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm2 or less); Moderate to severe aortic insufficiency (echocardiographic assessment graded as ≥ +2); Severe peripheral arterial disease precluding placement of the Impella System; Significant right heart failure*; Combined cardiorespiratory failure*; Presence of an Atrial or Ventricular Septal Defect (including post-infarct VSD)*; Left ventricular rupture*; Cardiac tamponade*
* This condition is a contraindication for the cardiogenic shock indication only.
POTENTIAL ADVERSE EVENTS
Acute renal dysfunction, Aortic valve injury, Bleeding, Cardiogenic shock, Cerebral vascular accident/Stroke, Death, Hemolysis, Limb ischemia, Myocardial infarction, Renal failure, Thrombocytopenia and Vascular injury
In addition to the risks above, there are other WARNINGS and PRECAUTIONS associated with Impella devices. Visit http://www.abiomed.com/important-safety-information to learn more.
The Impella Connect® transfers the video image of the screen on the Automated Impella® Controller to an authorized remote user. The transmitted image can be viewed by authorized remote users. The users can include the hospital’s clinicians, Abiomed local support staff, and Customer Support Center (CSC) team members.
Impella Connect Precautions
- Impella Connect is not intended to provide real-time information for monitoring patient status on the Automated Impella® Controller.
- During use of the Impella Connect, there will be a delay between when an image appears on the controller screen and when it is displayed at a remote viewing location.
- The Impella Connect is not a source of patient alarms, nor is its use intended as a replacement for monitoring the controller’s alarms.
- During use of the Impella Connect, receipt of the displayed controller information is not confirmed by the Automated Impella® Controller, nor is the delivery of the displayed controller information to the authorized remote users guaranteed.
- The Impella Connect is not designed for use during transport.
- Radiated and conducted electromagnetic interference can affect the performance of the Impella Connect, causing a temporary loss of connectivity. To clear interference, either increase the distance between system components and the EMI source or turn off the EMI source. Any electromagnetic interference related to the Impella Connect will have no impact on any of the controller functional specifications.
- Portable and mobile RF communications equipment can affect medical electrical equipment.
General Indication and Safety Information
To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.protectedpci.com/indications-use-safety-information/